Picture two people who have never met, working on opposite ends of the same problem.
One is a farmer in the English Midlands, driving a sprayer across a potato field. Rain has been falling for days. Without a fungicide application, blight will take the crop. The chemical goes on.
The other is a physician in a hospital in Amsterdam, watching a patient with leukemia fail to respond to antifungal treatment. The fungus — Aspergillus fumigatus, inhaled from the environment — is resistant. The medication is not working.
These two stories seem unrelated. They are not.
The editorial “One health and resistant fungi: a challenging balancing act between food security and patient survival” makes the case that the farmer’s field and the doctor’s ward are connected by something invisible: shared chemistry, shared pressure, and fungi that evolve without asking anyone’s permission.
The Same Key, Two Different Doors
To understand the problem, you need to understand azoles.
Azoles are a family of antifungal compounds. In agriculture, they are sprayed onto crops to kill the fungi that cause disease. In medicine, they are prescribed to patients to treat fungal infections that could otherwise become fatal. The compounds are not identical across these two worlds — but they work in similar ways, targeting similar biological systems inside fungal cells, particularly the pathways that control how fungal membranes are built.
Think of it as a master key cut to fit slightly different locks. The key you use on the farm is not exactly the one used in the hospital. But the locks — the biological targets inside the fungus — are close enough that using one key changes how easily the other opens.
When fungi in agricultural environments are exposed repeatedly to azole fungicides, the ones that survive carry the genetic traits that helped them resist. Those traits do not disappear when the fungus leaves the field. If the same resistance mechanisms also work against medical azoles, then what began as a crop-protection problem becomes a treatment problem — in a hospital ward, with a vulnerable patient, where the options are already limited.
This is not speculation. This is the mechanism the editorial is warning about.
The Environmental Origin of Resistance
Most people assume that drug resistance develops inside patients — inside bodies, inside hospitals, through repeated treatment. For bacterial infections, that is often true.
Fungi are different.
Many of the fungi that infect humans are environmental organisms. They do not live primarily in people. They live in soil, in compost, in decaying vegetation, in agricultural fields, in water systems. Aspergillus fumigatus — the mold most commonly associated with serious invasive fungal infections in immunocompromised patients — is widespread in the environment. Its spores are in the air we breathe every day. For most people, exposure causes nothing. For a patient recovering from a bone marrow transplant or undergoing chemotherapy, it can be catastrophic.
The critical point is this: A. fumigatus does not need to evolve resistance inside a patient. It can acquire resistance in a compost heap. It can acquire it in a field where azole fungicides have been applied year after year. By the time it reaches a vulnerable person, the resistance is already there.
That changes everything about how we think about the problem. Resistance does not start at the bedside. It may start in the ecosystem — and travel from there.
Food Security Versus Patient Survival
Here is where the dilemma becomes genuinely hard.
Agricultural fungicides are not optional extras. Fungal diseases cost farmers billions of dollars annually and threaten the stability of food systems that billions of people depend on. Wheat blights, grape mildews, potato diseases — without fungicide protection, losses would be severe and in some cases catastrophic. Telling farmers to simply stop using azoles is not a policy. It is an abstraction.
At the same time, antifungal drugs are not optional either. For patients with cancer, organ transplants, HIV, or conditions requiring immunosuppression, invasive fungal infections are a leading cause of death. Azole antifungals are among the few effective treatments available. Losing them to resistance — even partial resistance — narrows the options in situations where options are already scarce.
Both needs are real. Both are urgent. And they are, at least partly, in tension with each other.
The editorial does not pretend otherwise. Its value is precisely that it names the conflict directly rather than dissolving it into comfortable language about “balance.” There is a balancing act here, and it is not easy.
Why One Health Is the Correct Framework
The One Health concept holds that human health, animal health, and environmental health are not separate domains. They are interconnected systems, and problems that appear in one will eventually surface in another.
Antifungal resistance is one of the clearest illustrations of why this framework exists.
A resistance gene that emerges in a field in the Netherlands can travel — on spores, on wind, on imported produce — to a hospital in another country. A surveillance system that only monitors resistance inside clinical settings will miss the signal entirely, because the signal originates somewhere else. A policy that addresses agricultural fungicide use without considering clinical antifungal stewardship will solve half the problem at best.
The people who need to talk to each other — plant pathologists, infectious disease specialists, environmental microbiologists, veterinarians, public health officials, agricultural regulators — rarely share a table. One Health is the argument that they must.
Smarter Stewardship, Not Simple Elimination
The practical answer is not elimination. It is stewardship — a word that gets used loosely but means something precise here.
In agriculture, stewardship means using fungicides in ways that slow resistance development: rotating chemical classes, reducing unnecessary applications, integrating non-chemical disease management, monitoring for resistance in field populations. None of these steps removes the fungicide. They change how it is used.
In medicine, stewardship means prescribing antifungals only when needed, using diagnostics to confirm infection before treatment, tracking resistance patterns in clinical isolates, and protecting drug classes that are running out of alternatives.
The harder piece — the one the editorial pushes hardest — is coordination between these two systems. An agricultural fungicide rotation designed without knowledge of clinical resistance patterns may inadvertently select for exactly the resistance that matters most in hospitals. A clinical surveillance program that does not track environmental resistance will be perpetually surprised by what it finds.
The Policy Meaning of the Article
This is an editorial, not a clinical trial. It does not generate new data. What it generates is clarity about a problem that is easy to misframe.
The temptation, when discussing agricultural fungicides and antifungal resistance, is to assign blame — to point at farmers, or at pharmaceutical companies, or at regulators who approved certain compounds. The editorial resists that temptation. The dilemma it describes is not the product of bad decisions. It is the product of two legitimate needs — feeding people and treating sick people — colliding in a world where fungi evolve faster than policy does.
That framing matters. It means the solution cannot be punitive. It has to be structural — built on shared surveillance, coordinated stewardship, and the willingness to treat a problem that crosses sector boundaries as one problem, not two.
FAQ: One Health and Resistant Fungi
What is the main argument of this editorial?
The editorial argues that antifungal resistance is a One Health issue because agriculture, medicine, veterinary practice, and environmental systems all use or influence antifungal pressure.
Why are agricultural fungicides important?
Agricultural fungicides protect crops from fungal diseases, reduce yield losses, and support food security. The article does not argue that they should simply be eliminated.
Why can fungicides affect medical antifungal resistance?
Some agricultural fungicides and medical antifungals are chemically related or target similar fungal pathways. This overlap may allow environmental resistance selection to affect clinical treatment options.
What does environmental resistance selection mean?
It means resistant fungi may be selected in soils, crops, compost, wastewater, or natural habitats before they ever infect humans.
Why is this a One Health problem?
Because fungal resistance connects human health, food production, animal health, and environmental ecology. No single sector can manage the risk alone.
What is the best solution?
The best path is coordinated stewardship: protecting crop production while preserving the effectiveness of life-saving antifungal medicines.
References
Hoenigl, M., & Gangneux, J.-P. (2026). One health and resistant fungi: a challenging balancing act between food security and patient survival. Expert Review of Anti-infective Therapy. https://doi.org/10.1080/14787210.2026.2646190
